Terms ending in 2031
Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US D775,945 | Package In force · High confidence | Haleon UK IP Limited | In force | High confidence | |
| US 8,410,103 | (3S,11aR)-N-[2,4-Difluorophenyl)METHYL]-6-Hydroxy-3-Methyl-5,7-Dioxo-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-Carboxamide USEFUL AS ANTI-HIV AGENT In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 8,273,782 | Inhibitors of Akt Activity In force · High confidence | Novartis AG | In force | High confidence | |
| US 9,023,842 | Benzodiazepine Bromodomain Inhibitor In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 9,102,677 | Benzodiazepine Bromodomain Inhibitor In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 8,887,659 | Continuous Coating of Pellets Grace period ended Nov 18, 2026 · lapse expected · Low confidence | GlaxoSmithKline LLC | Grace period ended Nov 18, 2026 lapse expected | Low confidence | |
| US 8,609,711 | Crystalline N-{(1S)-2-Amino-1-[(3-Fluorophenyl)METHYL]ETHYL}-5-Chloro-4-(4-Chloro-1-Methyl-1H-PYRAZOL-5-YL)-2-Thiophenecarboxamide Hydrochloride In force · High confidence | Novartis AG | In force | High confidence | |
| US 9,360,482 | Process for the Identification of a Compound Which Inhibits the Binding of the Second Bromodomain of Each of Human BRD-2, BRD-3, and BRD-4 In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 9,062,003 | Benzimidazole Derivatives as PI3 Kinase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 9,156,797 | Benzimidazole Derivatives As PI3 Kinase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| 3 more term ends in 2031 · Pro | |||||
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13.
10 of these are in force and held by GlaxoSmithKline LLC.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.